Stephan Stilgenbauer, MD, PhD of Ulm University, Ulm, Germany, discusses the role of transplantation in chronic lymphocytic leukemia (CLL). A transplant has been and still is the only approach which holds a chance of cure. Prof. Stilgenbauer explains that with the much improved treatments available today, such as venetoclax, idelalisib, or ibrutinib, transplant has been moved to later in the lines of treatment. One of the most critical points in patient management in CLL remains the issue of not missing the point in time when to perform the transplant; this is important in particular when patients fail one or two types of the novel treatments, or when Richter’s transformation occurs. He further explains that it would be extremely beneficial to find ways to detect the risk of this before it happens, as these patients are still candidates for transplant, and especially as this approach offers the only long term chance for disease control for them. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.